Non alcoholic fatty liver disease is a disease of emerging identity and importance. It is frequently associated with obesity, especially visceral fat, and is intimately related to fatty liver and markers of insulin resistance. Both the prevalence and the severity of liver steatosis are related to body mass index, waist circumference, hyperinsulinaemia, hypertriglyceridaemia and impaired glucose...

Non-alcoholic steatohepatitis, one form of the non-alcoholic fatty liver disease spectrum, has been associated with obesity and lipid dysregulation. The patient usually presents with abnormal lipid and liver profiles. The most evidence based treatment for non-alcoholic steatohepatitis involves around weight loss, glycemic control and avoiding liver insulting drugs. Our current understanding of ...

conclusions in view of the limitations of the above-mentioned modalities, liver biopsy remains the gold standard method for documentation of diagnosis and estimation of disease severity in nafld. context considering the increasing prevalence of obesity and insulin resistance syndrome worldwide, non-alcoholic fatty liver disease (nafld) has become a major health concern. early diagnosis and prop...

Obesity and metabolic syndrome are healthcare problems that continue to rise in frequency worldwide. Both phenotypes are a strong predictor for development of liver steatosis in the context of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis. Ultrasound may detect steatosis, but its sensitivity is limited and liver biopsy is still considered to be the gold standard. Less invas...

background: despite the prevalence of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), no treatment has been proven to be effective in these common diseases. although many studies have shown that lifestyle modifications such as increasing physical activities and exercise could be effective in the treatment of these common diseases, the optimal strategy is stil...

Sodium glucose cotransporter 2 inhibitors are expected to ameliorate the abnormalities associated with metabolic syndrome including non-alcoholic fatty liver disease. In this study, we investigated the effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on the development of non-alcoholic fatty liver disease-related liver tumorigenesis in C57BL/KsJ-+Lepr db /+Lepr db obese and...

background: non-alcoholic fatty liver disease (nafld) is increasingly a common disease which is created by the accumulation of fat in the liver. about 20% of adults and 5% of children suffer from this disease. in some studies, half of obese children had fatty liver disease and approximately 90% of the patients with fatty liver were obese. the aim of this study was to evaluate fatty liver diseas...